BUZZ - India's Kotak Mahindra Bank shares rise on second quarter loan growth; Goldman Sachs reiterates 'Buy' rating
路透社2026/10/06 04:46October 6 – ** Shares of India’s Kotak Mahindra Bank KTKM.NS rose 3.3% to 429.80 rupees ** Kotak Mahindra Bank reported a 24.7% increase in net loans for Q2 FY2027 (link) ** Goldman Sachs reiterated its “Buy” rating with a target price of 540 rupees, citing the better-than-expected Q2 performance update ** Given strong deposit growth and organic loan expansion, the bank’s EPS compound annual growth rate (CAGR) estimate for FY2026-29 was raised to 19% ** It was noted that organic loan growth rose from 15% in the previous quarter to 19% year-on-year; this growth momentum is expected to continue, supported by retail loans, SME lending, and commercial banking ** An average of 37 analysts give the stock a “Buy” rating, with a median target price of 470 rupees – data compiled by LSEG ** Year-to-date, the stock is down 5.5% (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Due to the possibility of errors or lack of required context in automated translations, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
October 6 - ** Shares of Kotak Mahindra Bank KTKM.NS rose 3.3% to 429.80 rupees
** Kotak Mahindra Bank reported that its net loans for the second quarter of fiscal year 2027 (link) grew by 24.7%
** Goldman Sachs reaffirmed its "Buy" rating with a target price of 540 rupees, citing better-than-expected Q2 earnings
** Upgraded its compound annual growth rate (CAGR) forecast for earnings per share in FY2026-29 to 19%, given strong deposit growth and organic loan expansion
** Noted that organic loan growth rate rose to 19% (year-on-year) from 15% in the previous quarter; expects this momentum to continue, driven by retail lending, SME loans, and commercial banking
** On average, 37 analysts have a "Buy" rating on the stock, with a median target price of 470 rupees—data compiled by LSEG
** The stock has fallen 5.5% year-to-date
(To assist those whose native language is not English, Reuters has automated translations of its reports into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text. The automated translation is only provided for reader convenience. Reuters accepts no liability for any damage or loss resulting from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Downside risks with 1.1100 in sight against US Dollar – ING
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
